gemfibrozil

Summary

Summary: A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Top Publications

  1. Manzoori J, Amjadi M. Spectrofluorimetric and micelle-enhanced spectrofluorimetric methods for the determination of gemfibrozil in pharmaceutical preparations. J Pharm Biomed Anal. 2003;31:507-13 pubmed
    A spectrofluorimetric method for the determination of antihyperlipoproteinemic gemfibrozil was developed based on its native fluorescence. This method allows the determination of 0...
  2. Skolness S, Durhan E, Jensen K, Kahl M, Makynen E, Villeneuve D, et al. Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas). Environ Toxicol Chem. 2012;31:2615-24 pubmed publisher
    ..b>Gemfibrozil is a fibrate that has been detected in wastewater treatment plant influents, effluents, and drinking water...
  3. Hoose S, Duran C, Malik I, Eslamfam S, Shasserre S, Downing S, et al. Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. PLoS ONE. 2012;7:e36503 pubmed publisher
    ..We show that the antilipemic gemfibrozil delays initiation of DNA replication, while cells treated with the antidepressant fluoxetine severely delay ..
  4. Sakai T, Kamanna V, Kashyap M. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001;21:1783-9 pubmed
    ..This study examined the effect of extended-release niacin (niacin-ER) and gemfibrozil on LP-AI and LP-AI+AII particles in patients with low levels of HDL cholesterol (HDL-C)...
  5. Kyrklund C, Backman J, Kivistö K, Neuvonen M, Laitila J, Neuvonen P. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340-5 pubmed
    ..Our aim was to study the effects of bezafibrate and gemfibrozil on the pharmacokinetics of lovastatin.
  6. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan G. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66:1123-30 pubmed
    ..a post hoc subgroup analysis of a randomized double-blind, placebo-controlled trial to determine whether gemfibrozil is effective and safe for secondary prevention of cardiovascular events in individuals with chronic renal ..
  7. Jaakkola T, Backman J, Neuvonen M, Neuvonen P. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77:404-14 pubmed
    ..Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to determine the role of these ..
  8. Tenkanen L, Mänttäri M, Kovanen P, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-8 pubmed
    ..placebo-controlled primary prevention trial among 4081 dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart disease (CHD)...
  9. Insua A, Massari F, Rodríguez Moncalvo J, Rubén Zanchetta J, Insua A. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract. 2002;8:96-101 pubmed
    To compare the hypolipidemic effects of gemfibrozil and micronized fenofibrate in patients with primary hyperlipoproteinemia, phenotypes IIa and IIb, with emphasis on their cholesterol-lowering effectiveness.

Scientific Experts

More Information

Publications62

  1. Buyukcelik M, Anarat A, Bayazit A, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr. 2002;44:40-4 pubmed
    ..The present investigation was designed to evaluate the safety and efficacy of gemfibrozil in nephrotic children. Eight girls and four boys aged from 5 to 17 years were enrolled in this study...
  2. Tornio A, Neuvonen P, Backman J. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol. 2006;62:645-51 pubmed
    Zopiclone is a short acting hypnotic, which is metabolised by cytochrome P450 (CYP) 3A4 and 2C8 in vitro. We studied the possible effect of gemfibrozil, an inhibitor of CYP2C8, on the pharmacokinetics and pharmacodynamics of zopiclone.
  3. Almad A, Lash A, Wei P, Lovett Racke A, McTigue D. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011;232:309-17 pubmed publisher
    ..b>Gemfibrozil, an agonist of PPAR-?, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical signs ..
  4. Bloomfield Rubins H, Davenport J, Babikian V, Brass L, Collins D, Wexler L, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-33 pubmed
    ..A low level of HDL cholesterol has been identified as a risk factor for stroke in observational studies...
  5. Dasgupta S, Roy A, Jana M, Hartley D, Pahan K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol. 2007;72:934-46 pubmed
    The present study underlines the importance of gemfibrozil, a lipid-lowering drug and an activator of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), in inhibiting the disease process of adoptively transferred experimental ..
  6. Jones P, Davidson M. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-2 pubmed
    ..it is not known whether there are differences in the rate of myotoxicity between the use of fenofibrate and gemfibrozil in combination with statins...
  7. Hsu H, Lee Y, Yeh H, Chen M. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia. J Lab Clin Med. 2001;137:414-21 pubmed
    ..b>Gemfibrozil is widely used and is reported to decrease VLDL levels and increase HDL levels...
  8. Hashimoto F, Oguchi Y, Morita M, Matsuoka K, Takeda S, Kimura M, et al. PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. Biochem Pharmacol. 2004;68:313-21 pubmed
    We studied effects of PPARalpha agonists clofibric acid and gemfibrozil on cell growth and functions of immortalized human extravillous trophoblast cells. Levels of DNA and protein gradually increased during incubation for 4 days...
  9. Prueksaritanont T, Zhao J, Ma B, Roadcap B, Tang C, Qiu Y, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042-51 pubmed
    ..studies were conducted to explore the mechanism of the pharmacokinetic interaction between simvastatin (SV) and gemfibrozil (GFZ) reported recently in human subjects. After administration of a single dose of SV (4 mg/kg p.o...
  10. Aguilar Salinas C, Fanghanel Salmon G, Meza E, Montes J, Gulias Herrero A, Sanchez L, et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. Metabolism. 2001;50:729-33 pubmed
    ..The aim of this trial was to evaluate the efficacy and safety of ciprofibrate versus gemfibrozil for the treatment of patients with mixed hyperlipidemia carefully selected for similar lipid profiles...
  11. Noe J, Portmann R, Brun M, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35:1308-14 pubmed
    ..The gemfibrozil-statin interaction was studied at the level of active hepatic uptake as a model for such drug-drug interactions...
  12. Superko H, Garrett B, King S, Momary K, Chronos N, Wood P. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Am J Cardiol. 2009;103:387-92 pubmed publisher
    ..to determine, using analytic ultracentrifugation, the effect of nicotinic acid alone or nicotinic acid added to gemfibrozil on lipoprotein subclass distribution, including intermediate-density lipoprotein (IDL; low-density to very low ..
  13. Whitelaw D, Smith J, Nattrass M. Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes Obes Metab. 2002;4:187-94 pubmed
    ..triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 ..
  14. Phelps L, Peuler J. Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. J Smooth Muscle Res. 2010;46:125-42 pubmed
    ..Accordingly, we tested gemfibrozil which is resistant to photodegradation...
  15. Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact. 2004;20:25-42 pubmed
    ..In the presence of gemfibrozil, the CYP- or UGT-mediated metabolism of pitavastatin was inhibited in vitro...
  16. Niemi M, Backman J, Neuvonen M, Neuvonen P. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46:347-51 pubmed
    Our aim was to investigate possible interactions of gemfibrozil, itraconazole, and their combination with repaglinide.
  17. Tharappel J, Cunningham M, Spear B, Glauert H. Differential activation of hepatic NF-kappaB in rats and hamsters by the peroxisome proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate. Toxicol Sci. 2001;62:20-7 pubmed
    ..The peroxisome proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate were administered to animals for 6, 34, or 90 days...
  18. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug intera. J Pharmacol Exp Ther. 2004;311:228-36 pubmed
    A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported...
  19. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen P, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther. 2008;84:403-11 pubmed publisher
    Repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and 3A4. Gemfibrozil has the effect of increasing the area under the concentration-time curve (AUC) of repaglinide eightfold...
  20. Rizvi F, Iftikhar M, George J. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food. 2003;6:123-8 pubmed
    ..Treatment with fish liver preparations (FLPs) from sea bass and the standard drug gemfibrozil produced a lowering of serum lipids and glucose levels, along with a fall in very-low-density and low-density ..
  21. Sutken E, Inal M, Ozdemir F. Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. Saudi Med J. 2006;27:453-9 pubmed
    This study has dealt with the effects of gemfibrozil and vitamin E (vit E) therapies on lipoprotein levels, lipid peroxidation and antioxidant statuses of the elderly and young hyperlipidemic subjects.
  22. Calkin A, Cooper M, Jandeleit Dahm K, Allen T. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 2006;49:766-74 pubmed
    ..We investigated putative mechanisms responsible for these anti-atherogenic effects in an in vivo model of diabetes-associated atherosclerosis...
  23. Bergman E, Matsson E, Hedeland M, Bondesson U, Knutson L, Lennernas H. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol. 2010;50:1039-49 pubmed publisher
    The effect of a single intrajejunal dose of gemfibrozil (600 mg) on the plasma pharmacokinetics and biliary excretion of a single intrajejunal dose of rosuvastatin (20 mg) was investigated by using a multichannel catheter positioned in ..
  24. Syvanne M, Whittall R, Turpeinen U, Nieminen M, Frick M, Kesaniemi Y, et al. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis. 2004;172:267-72 pubmed
    The present study aimed to assess the effect of gemfibrozil on serum total homocysteine (tHcy) concentration and to evaluate the influence of tHcy on the angiographically determined progression of coronary atherosclerosis in a randomised,..
  25. Prindiville J, Mennigen J, Zamora J, Moon T, Weber J. The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout. Toxicol Appl Pharmacol. 2011;251:201-8 pubmed publisher
    b>Gemfibrozil (GEM) is a fibrate drug consistently found in effluents from sewage treatment plants. This study characterizes the pharmacological effects of GEM on the plasma lipoproteins of rainbow trout (Oncorhynchus mykiss)...
  26. Bosse Y, Vohl M, Dumont M, Brochu M, Bergeron J, Despres J, et al. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet. 2002;62:45-52 pubmed
    ..lipid and lipoprotein levels, 65 dyslipidemic abdominally obese men were treated for 6 months with or without gemfibrozil (600 mg twice daily)...
  27. Schneck D, Birmingham B, Zalikowski J, Mitchell P, Wang Y, Martin P, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-63 pubmed
    Coadministration of statins and gemfibrozil is associated with an increased risk for myopathy, which may be due in part to a pharmacokinetic interaction...
  28. Kang X, Wang F, Xie Z, Li H. A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:645-8 pubmed publisher
    ..liquid chromatography (HPLC) method was developed for the simultaneous determination of rosiglitazone and gemfibrozil in human plasma using alpha-asarone as an internal standard (IS)...
  29. Liu A, Yang J, Zhao X, Jiao X, Zhao W, Ma Q, et al. Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. Pharmacol Rep. 2011;63:157-64 pubmed
    ..b>Gemfibrozil is one of the most commonly used fibrates, and it shows the highest risk for myotoxicity among the fibrates...
  30. De Filippis B, Giancristofaro A, Ammazzalorso A, D angelo A, Fantacuzzi M, Giampietro L, et al. Discovery of gemfibrozil analogues that activate PPAR? and enhance the expression of gene CPT1A involved in fatty acids catabolism. Eur J Med Chem. 2011;46:5218-24 pubmed publisher
    A new series of gemfibrozil analogues conjugated with ?-asarone, trans-stilbene, chalcone, and their bioisosteric modifications were synthesized and evaluated to develop PPAR? agonists...
  31. Corbett G, Roy A, Pahan K. Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012;189:1002-13 pubmed publisher
    ..The present study underlines a novel application of gemfibrozil (gem), a Food and Drug Administration-approved lipid-lowering drug, in increasing the expression of IL-1Ra in ..
  32. Jin L, Cao Q. Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats. Arzneimittelforschung. 2012;62:40-5 pubmed publisher
    ..The effect of gemfibrozil on the pharmacokinetics of orally administered mitiglinide in rats was investigated...
  33. Bruno Joyce J, Dugas J, MacCausland O. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother. 2001;35:1016-9 pubmed
    To report a case of rhabdomyolysis resulting from concurrent use of cerivastatin and gemfibrozil. CASE SUMMARY An 82-year-old white man presented to the emergency department with severe muscle weakness and inability to walk approximately ..
  34. Wägner A, Jorba O, Bonet R, Ordonez Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2003;88:3212-7 pubmed
    To compare the effects of atorvastatin, gemfibrozil, and their combination on the components of diabetic dyslipidemia, 44 type 2 diabetic patients with low density lipoprotein cholesterol (LDLc) levels greater than 100 mg/dl and ..
  35. Despres J, Lemieux I, Pascot A, Almeras N, Dumont M, Nadeau A, et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2003;23:702-3 pubmed
  36. Deng L, Wang F, Li H. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol. 2005;61:831-6 pubmed
    Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4.
  37. Ozansoy G, Akin F. Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol. 2004;56:241-6 pubmed
    The effects of gemfibrozil treatment on plasma lipids, lipid peroxides and vascular reactivity of aorta were investigated in diabetic rats. Rats were divided randomly into two groups: control and diabetic...
  38. Superko H, Berneis K, Williams P, Rizzo M, Wood P. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol. 2005;96:1266-72 pubmed
    We tested the hypothesis that gemfibrozil has a differential effect on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclass distributions and postprandial lipemia that is different in subjects classified as having ..
  39. Lilja J, Backman J, Neuvonen P. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:433-9 pubmed
    Case reports suggest that gemfobrozil can increase the anticoagulant effect of warfarin. Because gemfibrozil inhibits CYP2C9 in vitro, we studied its effects on the pharmacokinetics and pharmacodynamics of racemic warfarin.
  40. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan G. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44:832-9 pubmed
    ..We conducted this study to determine whether gemfibrozil reduced rates of renal function loss in people with moderate CRI.
  41. Lamendola C, Abbasi F, Chu J, Hutchinson H, Cain V, Leary E, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol. 2005;95:189-93 pubmed
    ..dyslipidemia, 39 patients with this abnormality were assessed before and after 3 months of treatment with gemfibrozil (1,200 mg/day) or rosuvastatin (40 mg/day) with regard to: (1) steady-state plasma glucose concentration at the ..
  42. Martinez E, Domingo P, Ribera E, Milinkovic A, Arroyo J, Conget I, et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther. 2003;8:403-10 pubmed
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  43. Martinac A, Filipovic Grcic J, Barbarić M, Zorc B, Voinovich D, Jalsenjak I. Gemfibrozil encapsulation and release from microspheres and macromolecular conjugates. Eur J Pharm Sci. 2002;17:207-16 pubmed
    ..and compare the ability of the macromolecular conjugates and microspheres to modify the release rate of gemfibrozil (Gem)...
  44. Fang Y, Karnjanapiboonwong A, Chase D, Wang J, Morse A, Anderson T. Occurrence, fate, and persistence of gemfibrozil in water and soil. Environ Toxicol Chem. 2012;31:550-5 pubmed publisher
    ..The occurrence of gemfibrozil, a lipid-regulating drug, was studied in the influent and effluent at a wastewater treatment plant (WWTP) and ..
  45. Karpe F, Taskinen M, Nieminen M, Frick M, Kesaniemi Y, Pasternack A, et al. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis. 2001;157:181-7 pubmed
    ..outcome of the 2-year, randomised, placebo-controlled Lipid Coronary Angiography Trial (LOCAT), which used gemfibrozil as lipid lowering agent. The RLP-C response to gemfibrozil treatment has not been described before...
  46. Qandil A, Rezigue M, Tashtoush B. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. Eur J Pharm Sci. 2011;43:99-108 pubmed publisher
    ..Herein, we describe a covalent codrug of gemfibrozil (GEM) and nicotinic acid (NA) that was synthesized and characterized by (1)H NMR, (13)C NMR, FT-IR, MS analysis ..
  47. Duez H, Lefebvre B, Poulain P, Torra I, Percevault F, Luc G, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol. 2005;25:585-91 pubmed
    The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I.
  48. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mullbacher A, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007;51:2965-8 pubmed
    b>Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/..
  49. Rotllan N, Llaverias G, Julve J, Jauhiainen M, Calpe Berdiel L, Hernandez C, et al. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim Biophys Acta. 2011;1811:104-10 pubmed publisher
    b>Gemfibrozil and fenofibrate, two of the fibrates most used in clinical practice, raise HDL cholesterol (HDLc) and are thought to reduce the risk of atherosclerotic cardiovascular disease...
  50. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, et al. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos. 2009;37:2349-58 pubmed publisher
    ..along with the impact of concomitant dosing with two known multiple transport inhibitors; cyclosporine and gemfibrozil. Rosuvastatin (80 mg) was administered as an intrajejunal bolus dose in treatments I, II, and III (TI, TII, and ..
  51. Kalliokoski A, Backman J, Kurkinen K, Neuvonen P, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008;84:488-96 pubmed
    In a randomized crossover study, 24 SLCO181-genotyped healthy volunteers were given daily doses of 1,200 mg gemfibrozil, 40 mg atorvastatin, or placebo, followed by 0.25 mg of repaglinide on day 3...
  52. Vittal S, Shitut N, Kumar T, Vinu M, Mullangi R, Srinivas N. Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr. 2006;20:1252-9 pubmed
    ..liquid chromatography method is described for simultaneous determination of rosuvastatin (RST) and gemfibrozil (GFZ) in human plasma using celecoxib as an internal standard (IS)...
  53. Avogaro A, Miola M, Favaro A, Gottardo L, Pacini G, Manzato E, et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest. 2001;31:603-9 pubmed
    ..Endothelial dysfunction is an early feature of atherosclerosis. The relationship between insulin action and hypertriglyceridaemia on endothelial function is still debated...